Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, by Product Type (Pre-filled syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, and Others), by Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-

Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, by Product Type (Pre-filled syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, and Others), by Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-Thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, and Others), and by Mode of Delivery (Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), and Others (Epidural and Intrathecal) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site. Injectable delivery facilitates rapid absorption of drug from various route of administration such as subcutaneous, intravenous, and intramuscular. Injectable delivery increases the bioavailability of the drug at the systemic circulation. The increasing prevalence of chronic diseases, technological advancements, demand for individual therapy, awareness about drug metabolism among the population, and requirement of controlled drug release are the major factors driving the growth of the Brazil injectable drugs market for hospitals & ambulatory settings.
Brazil injectable drugs market for hospitals & ambulatory settings is estimated to be valued at US$ 7,960.0 Mn in 2021 and is expected to increase to US$ 17,858.5 Mn by 2028, witnessing a CAGR of 8.4% during the forecast period.
Market Dynamics
Increasing government initiatives in the healthcare sector of Brazil, rising drug launches and approvals, increasing prevalence of chronic diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Brazil injectable drugs market for hospitals & ambulatory settings.
The healthcare sector of Brazil is witnessing significant reforms in recent times owing to increasing initiatives by the government, agreements between multinational pharmaceutical companies and rising healthcare expenditure which is driving growth of the Brazil injectable drugs market for hospitals and ambulatory settings.
For instance, in June 2021, the government of Brazil announced an agreement with Oxford University and pharmaceutical company, AstraZeneca, to produce a promising coronavirus vaccine that is undergoing tests. The Brazilian Health Ministry said in a press conference that the country will pay US$ 127 million and receive material to produce 30.4 million doses in two batches in December and January.
Furthermore, in June 2019, government of the state of São Paulo, Brazil announced that they are seeking volunteers to test a new injectable drug preventing HIV infection using long-term injections as an alternative to the daily oral medication.
Moreover, increasing vaccination drives for certain diseases are also expected to aid growth of the Brazil Injectable drugs market for hospitals and ambulatory settings. For instance, in March 2021, Brazil initiated its National Flu Vaccination Campaign in three phases against influenza. The vaccine is indicated for anyone over 6 months of age, except those who have had allergic reactions to previous doses.
Key features of the study:
This report provides an in-depth analysis of the Brazil injectable drugs market for hospitals & ambulatory settings market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Brazil injectable drugs market for hospitals & ambulatory settings, based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Becton, Dickinson and Company, Pfizer, Inc., Novo Nordisk A/S, Gerresheimer AG, B. Braun Medical Inc., Grifols S.A, Baxter International, Inc., Fresenius Kabi AG, Mylan N.V., Bayer AG, F. Hoffmann-La Roche AG, Farmoquimica S.A., Novartis International AG, Eli Lily and Company, União Química Farmacêutica, Nacional S.A., Cristália, Aspen Pharmacare Holdings Limited, Blau Farmaceutica S.A., Halex Istar Indústria, Farmacêutica SA, Eurofarma, Ache Laboratorios Farmaceuticos SA, Laboratorio Teuto Brasileiro S/A, EMS Pharma, and Hipolabor Farmaceutica Ltda.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Brazil injectable drugs market for hospitals & ambulatory settings report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Brazil injectable drugs market for hospitals & ambulatory settings
Detailed Segmentation:
Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Product Type:
Pre-filled syringes
Auto-injectors
Pre-filled Pens
Pre-mixed IV Bags
Others
Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Drug Class:
Anesthesia
Antibiotics
Antidotes
Antiemetic
Anti-infective
Anti-Thrombolytic
Muscle Relaxant
Non Opioids
Opioids
Sedatives
Others
Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Mode of Delivery:
Intramuscular (IM)
Intravenous (IV)
Subcutaneous (SC)
Others (Epidural and Intrathecal)
Company Profiles
Becton, Dickinson and Company*
Company highlights
Product Portfolio
Key Highlights
Financial performance
Strategies
Pfizer Inc.
Novo Nordisk A/S
Gerresheimer AG
B. Braun Medical Inc.
Grifols S.A.
Baxter International, Inc.
Fresenius Kabi AG
Mylan N.V.
Bayer AG
F. Hoffmann-La Roche AG
Farmoquimica S.A.
Novartis International AG
Eli Lily and Company
União Química Farmacêutica
Nacional S.A.
Cristália
Aspen Pharmacare Holdings Limited
Blau Farmaceutica S.A.
Halex Istar Indústria
Farmacêutica SA
Eurofarma
Ache Laboratorios Farmaceuticos SA
Laboratorio Teuto Brasileiro S/A
Hipolabor Farmaceutica Ltda.
EMS Pharma
“*” marked represents similar segmentation in other categories in the respective section.